averag growth drive beat
top bottom line beat guidanc up
report revenu consensu estim driven
strong soliri strensiq perform bottom line beat estim vs
consensu driven higher expect revenu lower expect
expens also updat revenu guidanc includ
soliri metabol franchis revenu
includ favor fx benefit unfavor impact
soliri sale enrol non-gaap sg guidanc
lower revenu oper margin guidanc
increas adjust ep guidanc also rais
adjust ep accordingli reiter buy
consist growth strong gmg launch
gmg launch continu strong
us gmg patient soliri therapi end june patient
enrol onesourc system reiter expect gmg best
soliri launch thu far expect see current trajectori continu strong
underli growth come soliri pnh ahu gmg repres key
opportun bolster alxn top-line growth despit higher guidanc today
see room upward revis given strength gmg launch
pipelin opportun outsid complement
submit approv pnh us eu japanes
submiss expect view abl rapidli convert
soliri patient meanwhil phase data ahu
delay earli file submit pnh approv
phase bridg studi subcutan weekli expect initi
bla higher concentr iv formul would
reduc infus time expect long term plan
studi halo qm sc dose outsid
complement plan test superior soc wilson diseas
full definit iqmethod sm measur see page
bofa merril lynch seek busi issuer cover research report
result investor awar firm may conflict interest could
affect object report investor consid report singl
factor make invest decis
refer import disclosur page analyst certif page price object
basis/risk page
net dbt
return capit employ
return equiti
iqmethod sm qualiti earn
net incom cont oper
chang work capit
full definit iqmethod sm measur see page
biotechnolog compani market
soliri monoclon antibodi therapi
treatment ultra-rar diseas includ
paroxysm nocturn hemoglobinuria pnh
compani also market strensiq treatment
hypophosphatasia kanuma lal-d
focu sever life threaten ultra rare
rate buy expect industri
growth compani market product soliri
success launch new product
strensiq kanuma see upsid risk street
estim addit pipelin
momentum creat news flow
price object base discount cash flow analysi use
wacc termin growth rate
downsid risk failur meet expect soliri sale and/or launch
strensiq asfotas alfa kanuma lal-d govern drug price
focu ultra-orphan product failur advanc key pipelin product includ
soliri new indic
ying huang herebi certifi view express research report accur
reflect person view subject secur issuer also certifi
part compens directli indirectli relat specif
recommend view express research report
qualiti earn
iqmethod smi set bofa merril lynch standard measur serv maintain global consist three broad head busi perform qualiti earn valid key featur
iqmethod consist structur detail transpar methodolog guidelin maxim effect compar valuat process identifi common pitfal
iqdatabas real-tim global research databas sourc directli equiti analyst earn model includ forecast well histor data incom statement balanc sheet cash
flow statement compani cover bofa merril lynch
iqprofil sm iqmethod sm servic mark america corpor iqdatabas regist servic mark america corpor
